Krystal Biotech files patent response citing single-patient KB801 corneal closure

Krystal Biotech disclosed a single-patient corneal epithelial defect closure in a patent office response for KB801.

Key Highlights:

• Filed a USPTO response for a published patent application covering KB801, its gene therapy for neurotrophic keratitis.
• Response included data showing complete closure of a persistent corneal epithelial defect in one patient from a discontinued study.
• Study was discontinued to advance KB801 into a pivotal trial; no safety concerns or serious adverse events were observed in the study.
• Company had not previously disclosed the single-patient observation and shared it to ensure public access via the patent record.
• Company cautions the observation is from one patient, not top-line trial results, and will report pivotal trial results in the ordinary course.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.